19 research outputs found
An analysis of the carbon balance of the Arctic Basin from 1997 to 2006
Author Posting. © The Authors, 2010. This is the author's version of the work. It is posted here by permission of John Wiley & Sons for personal use, not for redistribution. The definitive version was published in Tellus B 62 (2010): 455-474, doi:10.1111/j.1600-0889.2010.00497.x.This study used several model-based tools to analyze the dynamics of the Arctic Basin between
1997 and 2006 as a linked system of land-ocean-atmosphere C exchange. The analysis estimates
that terrestrial areas of the Arctic Basin lost 62.9 Tg C yr-1 and that the Arctic Ocean gained 94.1
Tg C yr-1. Arctic lands and oceans were a net CO2 sink of 108.9 Tg C yr-1, which is within the
range of uncertainty in estimates from atmospheric inversions. Although both lands and oceans
of the Arctic were estimated to be CO2 sinks, the land sink diminished in strength because of
increased fire disturbance compared to previous decades, while the ocean sink increased in
strength because of increased biological pump activity associated with reduced sea ice cover.
Terrestrial areas of the Arctic were a net source of 41.5 Tg CH4 yr-1 that increased by 0.6 Tg CH4
yr-1 during the decade of analysis, a magnitude that is comparable with an atmospheric inversion
of CH4. Because the radiative forcing of the estimated CH4 emissions is much greater than the
CO2 sink, the analysis suggests that the Arctic Basin is a substantial net source of green house
gas forcing to the climate system.This study was supported, in part, by the NSF Arctic
System Science Program as part of the Arctic Carbon Cycle Synthesis Project (ARC-0531047,
0531082, 0531119, and 0554811)
Molecular basis of USP7 inhibition by selective small-molecule inhibitors
Ubiquitination controls the stability of most cellular proteins, and its deregulation contributes to human diseases including cancer. Deubiquitinases remove ubiquitin from proteins, and their inhibition can induce the degradation of selected proteins, potentially including otherwise 'undruggable' targets. For example, the inhibition of ubiquitin-specific protease 7 (USP7) results in the degradation of the oncogenic E3 ligase MDM2, and leads to re-activation of the tumour suppressor p53 in various cancers. Here we report that two compounds, FT671 and FT827, inhibit USP7 with high affinity and specificity in vitro and within human cells. Co-crystal structures reveal that both compounds target a dynamic pocket near the catalytic centre of the auto-inhibited apo form of USP7, which differs from other USP deubiquitinases. Consistent with USP7 target engagement in cells, FT671 destabilizes USP7 substrates including MDM2, increases levels of p53, and results in the transcription of p53 target genes, induction of the tumour suppressor p21, and inhibition of tumour growth in mice
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer patients is debated. Here, we report the whole-genome sequencing of 485 chronic lymphocytic leukemia patients enrolled in clinical trials as part of the United Kingdom’s 100,000 Genomes Project. We identify an extended catalog of recurrent coding and noncoding genetic mutations that represents a source for future studies and provide the most complete high-resolution map of structural variants, copy number changes and global genome features including telomere length, mutational signatures and genomic complexity. We demonstrate the relationship of these features with clinical outcome and show that integration of 186 distinct recurrent genomic alterations defines five genomic subgroups that associate with response to therapy, refining conventional outcome prediction. While requiring independent validation, our findings highlight the potential of whole-genome sequencing to inform future risk stratification in chronic lymphocytic leukemia
Comparison of three stimulation-based training methods for management of medical emergencies
A Novel Class of Zinc-Binding Inhibitors for the Phosphatidylcholine-Preferring Phospholipase C from Bacillus
Tris(dimethylamino)sulfonium Difluorotrimethylsilicate, a Mild Reagent for the Removal of Silicon Protecting Groups
Identifying gene regulatory elements by genomic microarray mapping of DNaseI hypersensitive sites
The identification of cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements. Traditional methods used to identify DNaseI hypersensitive sites are cumbersome and can only be applied to short stretches of DNA at defined locations. Here we report the development of a novel genomic array-based approach to DNaseI hypersensitive site mapping (ADHM) that permits precise, large-scale identification of such sites from as few as 5 million cells. Using ADHM we identified all previously recognized hematopoietic regulatory elements across 200 kb of the mouse T-cell acute lymphocytic leukemia-1 (Tal1) locus, and, in addition, identified two novel elements within the locus, which show transcriptional regulatory activity. We further validated the ADHM protocol by mapping the DNaseI hypersensitive sites across 250 kb of the human TAL1 locus in CD34(+) primary stem/progenitor cells and K562 cells and by mapping the previously known DNaseI hypersensitive sites across 240 kb of the human α-globin locus in K562 cells. ADHM provides a powerful approach to identifying DNaseI hypersensitive sites across large genomic regions
Identifying gene regulatory elements by genomic microarray mapping of DNaseI hypersensitive sites
Discovery of Isoquinolinone Indole Acetic Acids as Antagonists of Chemoattractant Receptor Homologous Molecule Expressed on Th2 Cells (CRTH2) for the Treatment of Allergic Inflammatory Diseases
Previously
we reported the discovery of CRA-898 (<b>1</b>), a diazine indole
acetic acid containing CRTH2 antagonist. This compound had good in
vitro and in vivo potency, low rates of metabolism, moderate permeability,
and good oral bioavailability in rodents. However, it showed low oral
exposure in nonrodent safety species (dogs and monkeys). In the current
paper, we wish to report our efforts to understand and improve the
poor PK in nonrodents and development of a new isoquinolinone subseries
that led to identification of a new development candidate, CRA-680
(<b>44</b>). This compound was efficacious in both a house dust
mouse model of allergic lung inflammation (40 mg/kg qd) as well as
a guinea pig allergen challenge model of lung inflammation (20 mg/kg
bid)